XML 80 R71.htm IDEA: XBRL DOCUMENT v3.25.1
Balance Sheet Components - Additional Information (Detail) - USD ($)
 1 Months Ended 3 Months Ended 12 Months Ended
Jul. 31, 2024
Jun. 30, 2024
Dec. 31, 2024
Dec. 31, 2023
Jul. 31, 2021
Schedule of Available-for-sale Securities [Line Items]          
Other-than-temporary impairment loss     $ 0    
Litigation settlement receivable     28,500,000 $ 28,500,000  
Depreciation expense for the continuing operations     2,654,000 9,518,000  
Depreciation expense for continuing operations     1,200,000 7,000,000  
API and bulk drug product price true-up     13,071,000 50,978,000  
Short-term investments     0 121,898,000  
Long-term investment     0    
Accrued litigation settlement     28,500,000 28,500,000  
Loss on disposal     2,500,000    
Restructuring plan, expected reduction to workforce, percentage 75.00%        
Restructuring plan, non-recurring charges     19,454,000 12,606,000  
Cash payments for restructuring     16,500,000    
Accrued restructuring charges     4,600,000 $ 3,700,000  
Eluminex Agreements [Member]          
Schedule of Available-for-sale Securities [Line Items]          
Aggregate consideration received for milestone and upfront payments         $ 8,000,000
Astellas Agreement [Member]          
Schedule of Available-for-sale Securities [Line Items]          
Payment to related parties   $ 35,300,000      
AstraZeneca Agreements [Member]          
Schedule of Available-for-sale Securities [Line Items]          
Payment to related parties   $ 11,500,000      
Inventory write-down     $ 12,600,000